Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||FLX475 + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FLX475||FLX-475|FLX 475||FLX475 is a CCR4 antagonist, which potentially results in increased effector T-cell and decreased regulatory T-cells within the tumor microenvironment, leading to antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 24 Immune Checkpoint Inhibitor 153||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04894994||Phase II||FLX475 + Ipilimumab||FLX475 in Combination With Ipilimumab in Advanced Melanoma||Terminated||USA||0|